 | • レポートコード：MRC2108A351 • 出版社/出版日：Mordor Intelligence / 2021年7月31日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、モノクローナル抗体の世界市場規模が2021年から2026年の間に8.51％成長すると予測しています。本調査資料では、世界のモノクローナル抗体市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製造方法別（イン・ビボ、イン・ビトロ）分析、原料別（キメラ、ヒト、ヒト化抗体、ネズミ科）分析、疾患別（癌、自己免疫疾患、感染症、炎症性疾患、その他）分析、エンドユーザー別（病院、研究機関、その他）分析、地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・モノクローナル抗体の世界市場規模：製造方法別（イン・ビボ、イン・ビトロ） ・モノクローナル抗体の世界市場規模：原料別（キメラ、ヒト、ヒト化抗体、ネズミ科） ・モノクローナル抗体の世界市場規模：疾患別（癌、自己免疫疾患、感染症、炎症性疾患、その他） ・モノクローナル抗体の世界市場規模：エンドユーザー別（病院、研究機関、その他） ・モノクローナル抗体の世界市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（Eli Lilly and Company、Johnson & Johnson、Merck KGaA、Pfizer, Inc.、GlaxoSmithKline PLC、Novartis AG、AstraZeneca PLC、Amgen, Inc.、AbbVie, Inc.、Bristol Myers Squibb Co.） ・市場機会/将来の見通し |
The monoclonal antibodies market is expected to register a CAGR of 8.51% during the forecast period of 2021-2026.
The monoclonal antibody production was halted due to the COVID-19 pandemic and it had severely affected the global monoclonal antibodies market as they are widely used in cancer and gene therapy, thus affecting the global monoclonal antibodies market. Although, when COVID-19 was at its peak in Europe and Unites States in 2020, few companies were working on new therapy based on monoclonal antibodies for the treatment of COVID-19. They isolated the COVID-19 antibodies from a recovered person and tested them as a cure for COVID-19 infection and they were successful and got approval for emergency use by the United States Food and Drug Administration. For example, in February 2021, the Food and Drug Administration permitted for emergency use of combined bamlanivimab and etesevimab therapy developed by Eli Lilly and Company for people having mild to moderate COVID-19 infection. And due to the potential application of monoclonal antibodies, it can be expected that COVID-19 will promote the global market of monoclonal antibodies.
The monoclonal antibodies are becoming ubiquitous in the treatment of different forms of cancer in developed countries and this has been attributed to the rapid growth of the global monoclonal antibodies market. According to the report of GOLOBOCAN 2020, there were 19.3 million new cases of cancer and about 10 million deaths due to cancer in the world and increasing cancer cases are the major growth factor behind the market. The other factors which will contribute positively towards the high growth of the global monoclonal antibodies market are new gene-based therapy, new research related to the application of monoclonal antibodies in treating some other deadly diseases like COVID-19, disease diagnostics, and treatment of other diseases like auto-immune, viral disease treatment and also the approval of new antibodies by governments will also lead to the growth of this market. For instance, in July 2020, Union Chimique Belge (UCB) did a license agreement with Roche and Genentech for the manufacturing and commercial production of UCB0107, which is a potent monoclonal antibody for the treatment of progressive supranuclear palsy (PSP) and Alzheimer’s disease, but it is still under investigation.
The cost associating with monoclonal antibodies is very high because of their complex manufacturing procedure and due to the cost involved in research and development and it is one of the major restraining factors for the growth of the global monoclonal antibodies market. The high cost of monoclonal antibodies is the main reason why it is still prevalent only in developed countries and not in developing and underdeveloped countries. Another factor responsible that can prove a restraint for this market will be the loss of patents by companies.
Key Market Trends
Cancer Monoclonal Antibodies is Estimated to Occupy a Significant Share in the Market over the Forecast Period
According to World Health Organization, cancer is the leading cause of death globally. As per the GLOBOCAN 2020 report, there were around 19.3 new cancer cases and about 10 million deaths due to cancer worldwide in 2020 and the most common types of cancer were breast cancer followed by lung cancer, rectal cancer, prostate cancer, and others. Due to the rising prevalence of cancer cases globally, in the global monoclonal antibodies market, cancer monoclonal antibodies will occupy a major market share.
Also, the global pharmaceutical companies are investing heavily in the research and development of cancer biologics drugs (monoclonal antibodies) because they are very efficient and non-toxic in the diagnostics and treatment of different types of cancer as compared to chemotherapy and other cancer treatment methods. and getting approvals for many new cancer monoclonal antibodies by the respective governments is more efficient and easy. According to an article published in December 2019 in Taylor & Francis Online, about 5 antibody therapeutics had been provided first approval in either European Union or the United States and these includes romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab. Polatuzimab vedotin (Polivy) was granted conditional marketing authorization in November 2019 for the treatment of relapsed /refractory diffuse large B-cell lymphoma. In another instance, in December 2020, the United States Food and Drug Administration approved MacroGenics’ MARGENZATM for the treatment of patients with pretreated metastatic HER2-positive breast cancer. These advancement may fuel the growth of monoclonal antibodies market.
North America is Expected to Dominate the Global Monoclonal Antibodies Market during the Forecast Period
North America is segmented into three countries – the United States, Canada, and Mexico. North America will dominate in the market share of global monoclonal antibodies because of the presence of standard nationwide healthcare system especially in the United States and Canada, huge funding by governments for the research and development of new biological therapies especially for cancer and new infectious diseases, rising geriatric population and diseases associated with them, and presence of key market players in the region during the forecast period. For example, in November 2020, the Government of Canada and Eli Lilly signed an agreement for a monoclonal antibody therapy called Bamlanivimab (LY-CoV555) for COVID-19 developed by Eli Lilly Company, a total of 26,000 doses were ordered initially.
Some of the key market players are headquartered in the United States who are actively involved in advancing the technique, launching new products, and forming strategic partnerships to have an edge in the monoclonal antibodies market. The government’s National Institute of Health and other related organizations are also engaged in the development of monoclonal antibodies and over the year had few breakthroughs. For instance, in August 2020, the National Institute of Health announced the launch of a clinical trial for two potential treatments of COVID-19 by using monoclonal antibodies. Also, the increasing cases of chronic diseases such as cancer will boost the growth of the market in the region. As per the GLOBOCAN 2020 report, 2,281,658 new cancer cases were diagnosed and 612,390 deaths due to cancer in the United States alone. The cancer cases in Canada and Mexico were 274,364 and 195,499, respectively. These factors are expected to drive the growth of studied market, over the forecast period.
Competitive Landscape
The global monoclonal antibodies market will be highly competitive with the number of established companies in the market and due to the new incoming companies, which are investing heavily in research and development with new and advanced technologies. In the current scenario, COVID-19 and cancer therapeutics will be the major domain of competition between the companies. Some of the major key players of the global monoclonal antibodies market are – Eli Lilly, F. Hoffmann-La Roche, Merck, Amgen Inc., Novartis AG, among others.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions & Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Technological Advancements
4.2.2 Increasing Burden of Cancer and Other Chronic Diseases
4.2.3 Huge Funding by Government for the Research and Development
4.3 Market Restraints
4.3.1 High Cost Pertaining to the Method Involved in the Production of Monoclonal Antibodies
4.3.2 Loss of Patents
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Production Methods
5.1.1 In vivo
5.1.2 In vitro
5.2 By Source
5.2.1 Chimeric
5.2.2 Human
5.2.3 Humanized
5.2.4 Murine
5.3 By Indications
5.3.1 Cancer
5.3.2 Autoimmune Diseases
5.3.3 Infectious Diseases
5.3.4 Inflammatory Diseases
5.3.5 Others
5.4 By End Users
5.4.1 Hospitals
5.4.2 Research Institutes
5.4.3 Others
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Johnson & Johnson
6.1.3 Merck KGaA
6.1.4 Pfizer, Inc.
6.1.5 GlaxoSmithKline PLC
6.1.6 Novartis AG
6.1.7 AstraZeneca PLC
6.1.8 Amgen, Inc.
6.1.9 AbbVie, Inc.
6.1.10 Bristol Myers Squibb Co.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS